A major comparative analysis has identified escitalopram as one of the strongest antidepressant options for preventing relapse in people treated for depression. The review found that three medicines ranked ahead of others in helping patients remain well after an initial response to treatment, with escitalopram outperforming fluoxetine, the drug widely known by the brand name Prozac.
The findings are relevant because relapse prevention is a central part of long-term mental health care. Many patients who improve on antidepressants continue treatment to reduce the risk of symptoms returning. In that phase, differences between medicines can matter, particularly when doctors and patients are weighing effectiveness against tolerability, prior response and individual health needs.
Escitalopram belongs to the selective serotonin reuptake inhibitor class, the same broad group as fluoxetine. Both are commonly used in the treatment of depression, but the analysis indicates that they may not perform equally when the goal is to prevent relapse across large patient groups. The result does not establish a single best medicine for every patient, but it adds evidence that could inform prescribing discussions in routine care.
Clinical decisions about antidepressants remain highly individualized. Factors such as side effects, interactions with other medicines, previous treatment history and patient preference can influence whether a drug is suitable. Public health guidance from institutions such as the NHS emphasizes that people taking antidepressants should not stop or change medication without medical advice, as abrupt changes can worsen symptoms or cause withdrawal effects.
The analysis strengthens the role of comparative evidence in psychiatry, where many treatments are available but their relative benefits can be difficult to judge in everyday practice. For clinicians, the key takeaway is not only that escitalopram performed strongly, but that relapse prevention should be treated as a distinct treatment goal after recovery begins.
